Final Height in Patients with Idiopathic Short Stature and High Growth Hormone Responses to Stimulation Tests

Children with idiopathic short stature (ISS) may have normal or increased growth hormone (GH) responses to provocation tests and achieve a final height (FH) below –2.0 standard deviation score (SDS) if untreated. FH of subjects with high stimulated GH levels has not been studied in detail. Aim: It was the aim of this study to analyse FH in ISS patients with high GH peak responses to the provocation test. Patients andMethods: We studied 16 patients (9 pre-pubertal) with ISS and a GH peak ≧40 mU/l to insulin-induced hypoglycaemia. The patients were recalled at age 19.7 ± 2.5 years for measurement of FH when blood samples were obtained for serum insulin-like growth factor (IGF)-I, IGF binding protein 3, acid-labile subunit and GH binding protein measurements. GH bioactivity was determined using the Nb2 bioassay. Results: FH was –3.1 ± 1.0 SDS, being significantly lower than target height (TH). At FH, IGF-I levels were within –1.5 and +1.5 SDS for age and sex in 10 patients and higher than +1.5 SDS in 6 patients. IGF binding protein 3, acid-labile subunit, GH binding protein levels and GH bioactivity values were normal. Summary: These data suggest that patients with ISS and high GH levels during a GH stimulation test may have a more compromised FH. The association of severe ISS with a peak GH >40 mU/l might suggest a degree of insensitivity for the GH-IGF-I axis.

[1]  G. Morcaldi,et al.  Heterozygous mutations of growth hormone receptor gene in children with idiopathic short stature. , 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[2]  L. Metherell,et al.  Diagnostic and therapeutic advances in growth hormone insensitivity. , 2005, Endocrinology and metabolism clinics of North America.

[3]  B. Little,et al.  Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. , 2005, The Journal of clinical endocrinology and metabolism.

[4]  M. Savage,et al.  Insulin-Like Growth Factor -I Deficiency , 2004, Hormone Research in Paediatrics.

[5]  Brenda J. Crowe,et al.  Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  B. Little,et al.  Growth hormone insensitivity associated with a STAT5b mutation. , 2003, The New England journal of medicine.

[7]  L. Metherell,et al.  Spontaneous growth hormone secretory characteristics in children with partial growth hormone insensitivity , 2002, Clinical endocrinology.

[8]  M. Preece,et al.  Clinical and Endocrine Characteristics in Atypical and Classical Growth Hormone Insensitivity Syndrome , 2001, Hormone Research in Paediatrics.

[9]  M. Caulfield,et al.  Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity. , 2001, American journal of human genetics.

[10]  L. Metherell,et al.  Growth Hormone Insensitivity: Pathophysiology, Diagnosis, Clinical Variation and Future Perspectives , 2001, Hormone Research in Paediatrics.

[11]  L. Ghizzoni,et al.  Growth Hormone Immunoreactivity Does Not Reflect Bioactivity , 2000, Pediatric Research.

[12]  M. M. Ilondo,et al.  Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: Summary statement of the GH research society , 2000 .

[13]  A. Rosenbloom.  Growth hormone insensitivity: physiologic and genetic basis, phenotype, and treatment. , 1999, The Journal of pediatrics.

[14]  M. Macgillivray,et al.  Comparison of final heights of growth hormone-treated vs. untreated children with idiopathic growth failure. , 1998, The Journal of clinical endocrinology and metabolism.

[15]  H. Kaji,et al.  Biologically inactive growth hormone caused by an amino acid substitution. , 1997, The Journal of clinical investigation.

[16]  L. Plotnick,et al.  Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature. , 1997, The Journal of pediatrics.

[17]  J. Guevara-Aguirre,et al.  Growth hormone insensitivity. , 1997, Current therapy in endocrinology and metabolism.

[18]  A. Clark,et al.  A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. , 1996, The Journal of clinical endocrinology and metabolism.

[19]  M. Dattani,et al.  The measurement of growth hormone bioactivity in patient serum using an eluted stain assay. , 1995, The Journal of clinical endocrinology and metabolism.

[20]  M. Binoux,et al.  Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. , 1986, Analytical biochemistry.

[21]  J. Tanner,et al.  Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. , 1976, Archives of disease in childhood.

[22]  J M Tanner,et al.  Standards for Children's Height at Ages 2-9 Years Allowing for Height of Parents , 1970, Archives of disease in childhood.

[23]  J M Tanner,et al.  Variations in the Pattern of Pubertal Changes in Boys , 1970, Archives of disease in childhood.

[24]  J M Tanner,et al.  Variations in pattern of pubertal changes in girls. , 1969, Archives of disease in childhood.

[25]  N. Bayley,et al.  Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. , 1952, The Journal of pediatrics.

[26]  A. Rosenbloom,et al.  IGF-I Deficiency Due to GH Receptor Deficiency , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.